Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States

Teeple, Amanda; Ginsburg, Shiphra; Howard, Leah; Huff, Laura; Reynolds, Caroline; Walls, Deborah G.; Ellis, Lorie; Curtis, Jeffrey R.

doi:10.1080/03007995.2018.1560221

Cited by 48 publications

(40 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Step 3: Construction of the intervention in a multidisciplinary fashion, based on the results of steps 1 and 2 and patients’ and rheumatologists ‘perception of BSs in published surveys. 16–18 29 No qualitative study was found in literature on patients’ perceptions of BSs.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar

et al. 2021

View full text Add to dashboard Cite

ObjectivesTo evaluate an intervention to reduce the nocebo effect (NE) when switching from the originator infliximab (OI) to the infliximab biosimilar SB2 in chronic inflammatory rheumatic disease (CIRD).MethodsAn intervention was built with healthcare professionals (HPs) and a patient representative, based on a systematic review of interventions reducing the NE in musculoskeletal diseases and semi-directed questioning of five patients. Our strategy consisted of training HPs, switch information given by the nurses, a consistent vocabulary. All CIRD patients switched from OI to SB2 were included for the intervention. The primary outcome was the SB2 retention rate (RR) at 34 weeks. Secondary outcomes were the SB2 RR at 12 months, discontinuation rates due to a possible NE and comparison with a historical cohort of CIRD patients receiving the OI and 6 published European cohorts.Results45 patients were included from March 2018 (rheumatoid arthritis, n=17, spondylarthritis, n=28). After 34 weeks, the SB2 RR was 91.2%, similar to the historical cohort RR (p=0.41) but higher than the 3 European cohort RRs (p<0.05). At 12 months, the SB2 RR was 84.5% vs 88.4% for the historical cohort (p=0.52). SB2 discontinuation due to a possible NE was 6.6% after 12 months.ConclusionsA tailored communication with a prominent role of nurses reduced the NE in non-medical switches from the OI to SB2 as compared to published results. The RR was similar to the historical cohort RR. The methodology used to construct this intervention may help improve the outcomes of switches with upcoming biosimilars.

show abstract

Section: Methodsmentioning

confidence: 99%

“…10–14 This is supported by reported concerns of patients about the efficacy (40–60%) and safety (35–57%) of BSs 15–17 and switches (83–85%). 18 Half of healthcare professionals also expressed concerns about switches. 19…”

Section: Introductionmentioning

confidence: 99%

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Among European patients with IBD who had heard of biosimilars, safety and efficacy were the most common concerns (47% and 39%, respectively), whereas around one-quarter of respondents had no specific concerns [168]. Furthermore, patients with autoimmune conditions expressed concerns that nonmedical switching could influence treatment outcomes [171].…”

Section: Patients' Perspective: Improved Information Sharing May Encomentioning

confidence: 99%

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Kim

Alten

Avedano³

et al. 2020

Drugs

View full text Add to dashboard Cite

Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.

show abstract

“…28,38 To this effect, in the survey-based study of US patients with CIDs by Teeple et al, 85% of patients were concerned that biosimilars would not treat their disease as well as the originator biologic. 39 Additionally, several observational studies have reported patients discontinuing biosimilars despite no change in disease activity and/or a lack of objective adverse events, suggesting subjective reasons for treatment discontinuation. 16,19,21 Alternatively, it is possible that switches away from biosimilars may just be a reflection of originator and biosimilar product availability.…”

Section: Discussionmentioning

confidence: 99%

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Fitzgerald

Melsheimer

Lafeuille

et al. 2021

BTT

View full text Add to dashboard Cite

Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States

Cited by 48 publications

References 9 publications

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Contact Info

Product

Resources

About